Anthem Capital Management

Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems for individuals with diabetes. Founded in 1996, the company focuses on innovative and long-term implantable glucose monitoring solutions that utilize advanced fluorescence sensing technology. Its flagship products, Eversense and Eversense XL, are implantable CGM systems designed to monitor glucose levels for up to 90 and 180 days, respectively. These products aim to provide users with a reliable and stable means of glucose management, enhancing their ability to live confidently and manage their diabetes effectively. The majority of Senseonics' revenue comes from international markets, reflecting its strong presence in Europe.

GlycoMimetics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative glycomimetic drugs aimed at addressing significant unmet medical needs associated with diseases influenced by carbohydrate biology. The company’s lead drug candidate, rivipansel, is a pan-selectin antagonist that has completed Phase III clinical trials for treating vaso-occlusive crises in sickle cell disease. Additionally, GlycoMimetics is developing uproleselan, an E-selectin inhibitor that is being tested in combination with chemotherapy for acute myeloid leukemia (AML) and in a Phase III trial for relapsed/refractory AML. The company also offers GMI-1359, which targets E-selectin and a chemokine receptor, having completed Phase I clinical trials, and is involved in developing other candidates, including GMI-1687 and Galectin-3. GlycoMimetics has established research collaborations, including an agreement with the National Cancer Institute and a partnership with Apollomics for the commercialization of uproleselan and GMI-1687. Founded in 2003, the company is headquartered in Rockville, Maryland.

Echo360, Inc. is a developer of a Software-as-a-Service learning and analytics platform tailored for higher education institutions both in the United States and internationally. Founded in 2007 and headquartered in Virginia, the company offers a comprehensive solution that enables users to capture, share, and enhance classroom experiences through features such as polls, quizzes, and instructional video recordings. Its platform facilitates connections between students and instructors worldwide and provides learning analytics to identify student engagement levels and potential challenges before exams. Additionally, Echo360 includes a learning library for storing educational materials, universal capture software for recording content on various devices, and an automatic speech recognition solution to support video-based learning. The company aims to transform educational experiences by leveraging active learning technology and interactive software to engage students effectively.

Siperian specializes in master data management (MDM) solutions that help organizations unify critical data about customers, products, and other entities that may be fragmented across various systems. By providing a comprehensive view of essential business information, Siperian enhances operational and analytical processes, allowing companies to make informed decisions and improve customer relationship management. The Siperian MDM Hub™ features a flexible, model-driven platform that adapts to specific business requirements, facilitating faster implementation and delivering a strong return on investment. Its solutions cater to a wide range of industries, including financial services, healthcare, manufacturing, and technology, addressing complex needs such as regulatory compliance and product launches. Siperian collaborates with a network of partners, including major firms like Accenture and IBM, to market and support its offerings. The company has earned the trust of numerous Fortune 500 clients, who rely on Siperian to manage large-scale master data solutions that support both analytical and transactional business needs.

RedLasso is a web-based platform that allows users to search and share licensed TV and radio broadcast clips. The service simplifies the process of finding professional broadcast news content and enables users to create and share their favorite clips online. Despite its innovative approach, the company faced legal challenges, including a Cease and Desist letter from several major media organizations. In response to these challenges, RedLasso appointed Michael Jordan, a former CEO of CBS and Westinghouse Corporation, as a senior advisor to navigate the evolving landscape of media sharing.

Defywire, Inc. develops wireless connections between teachers, administrators, students, and parents. The company offers Mobile Guardian, a web-based administration console that allows centralized management of mobile users, applications, and school configuration information. Its Mobile Guardian provides access to critical information, reconnecting through cellular, wireless fidelity, satellite, LAN or WAN, or other communication protocols, as well as supports blackberry and various Windows mobile devices, XP desktops, notebooks, and tablet PC's. The company was founded in 2003 and is based in Reston, Virginia.

GlycoMimetics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative glycomimetic drugs aimed at addressing significant unmet medical needs associated with diseases influenced by carbohydrate biology. The company’s lead drug candidate, rivipansel, is a pan-selectin antagonist that has completed Phase III clinical trials for treating vaso-occlusive crises in sickle cell disease. Additionally, GlycoMimetics is developing uproleselan, an E-selectin inhibitor that is being tested in combination with chemotherapy for acute myeloid leukemia (AML) and in a Phase III trial for relapsed/refractory AML. The company also offers GMI-1359, which targets E-selectin and a chemokine receptor, having completed Phase I clinical trials, and is involved in developing other candidates, including GMI-1687 and Galectin-3. GlycoMimetics has established research collaborations, including an agreement with the National Cancer Institute and a partnership with Apollomics for the commercialization of uproleselan and GMI-1687. Founded in 2003, the company is headquartered in Rockville, Maryland.

Qovia specializes in voice over Internet Protocol (VoIP) monitoring and management technologies. Founded in 2002 and based in Frederick, Maryland, the company develops software solutions designed to monitor and manage voice quality on VoIP telephone systems. Its products serve a diverse clientele, including school districts, government agencies, law enforcement, banking institutions, call centers, and voice carriers. By focusing on the quality of voice communications, Qovia plays a significant role in optimizing the performance of next-generation telephone systems that utilize internet technology for voice traffic.

Triumfant specializes in endpoint security software that offers continuous protection against advanced malware threats. The company utilizes intelligent, precision-based technology to detect and analyze cyberattacks, enabling immediate resolution of incidents that evade conventional, signature-based defenses. Triumfant's advanced detection capabilities minimize damage to enterprise systems and safeguard critical assets, ensuring that once an attacker gains access to a system, they cannot exfiltrate proprietary information. The software can halt a breach before it escalates into a full-scale attack and automatically repairs affected machines and any collateral damage within minutes, without requiring human intervention or causing system downtime. Organizations, including government entities, rely on Triumfant for rapid recovery and loss prevention in the event of cyberattacks.

Immune Control, Inc., founded in 2001 based on research from Drexel University College of Medicine, specializes in developing serotonin-based immunotherapeutics aimed at treating autoimmune and inflammatory diseases, hematologic cancers, and organ transplant rejection. The company's approach involves creating orally available small molecules that selectively modulate the immune system by targeting specific serotonin receptors on activated immune cells. This strategy seeks to provide a more favorable side effect profile compared to traditional treatments. Immune Control's initial focus was on utilizing an existing serotonin antagonist in clinical trials for multiple myeloma, with plans for further development contingent on positive trial outcomes. The company aims to identify and synthesize new compounds that are more potent and do not cross the blood-brain barrier, thus avoiding neurological side effects. Additionally, Immune Control actively protects its intellectual property through patents covering novel uses and compounds, bolstering its position in a market where the potential for treating related diseases exceeds a billion dollars.

Defywire, Inc. develops wireless connections between teachers, administrators, students, and parents. The company offers Mobile Guardian, a web-based administration console that allows centralized management of mobile users, applications, and school configuration information. Its Mobile Guardian provides access to critical information, reconnecting through cellular, wireless fidelity, satellite, LAN or WAN, or other communication protocols, as well as supports blackberry and various Windows mobile devices, XP desktops, notebooks, and tablet PC's. The company was founded in 2003 and is based in Reston, Virginia.

GlycoMimetics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative glycomimetic drugs aimed at addressing significant unmet medical needs associated with diseases influenced by carbohydrate biology. The company’s lead drug candidate, rivipansel, is a pan-selectin antagonist that has completed Phase III clinical trials for treating vaso-occlusive crises in sickle cell disease. Additionally, GlycoMimetics is developing uproleselan, an E-selectin inhibitor that is being tested in combination with chemotherapy for acute myeloid leukemia (AML) and in a Phase III trial for relapsed/refractory AML. The company also offers GMI-1359, which targets E-selectin and a chemokine receptor, having completed Phase I clinical trials, and is involved in developing other candidates, including GMI-1687 and Galectin-3. GlycoMimetics has established research collaborations, including an agreement with the National Cancer Institute and a partnership with Apollomics for the commercialization of uproleselan and GMI-1687. Founded in 2003, the company is headquartered in Rockville, Maryland.

Nucleonics is a biotechnology company focused on RNA interference-based therapeutics.

Qovia specializes in voice over Internet Protocol (VoIP) monitoring and management technologies. Founded in 2002 and based in Frederick, Maryland, the company develops software solutions designed to monitor and manage voice quality on VoIP telephone systems. Its products serve a diverse clientele, including school districts, government agencies, law enforcement, banking institutions, call centers, and voice carriers. By focusing on the quality of voice communications, Qovia plays a significant role in optimizing the performance of next-generation telephone systems that utilize internet technology for voice traffic.

BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.

Qovia specializes in voice over Internet Protocol (VoIP) monitoring and management technologies. Founded in 2002 and based in Frederick, Maryland, the company develops software solutions designed to monitor and manage voice quality on VoIP telephone systems. Its products serve a diverse clientele, including school districts, government agencies, law enforcement, banking institutions, call centers, and voice carriers. By focusing on the quality of voice communications, Qovia plays a significant role in optimizing the performance of next-generation telephone systems that utilize internet technology for voice traffic.

Defywire, Inc. develops wireless connections between teachers, administrators, students, and parents. The company offers Mobile Guardian, a web-based administration console that allows centralized management of mobile users, applications, and school configuration information. Its Mobile Guardian provides access to critical information, reconnecting through cellular, wireless fidelity, satellite, LAN or WAN, or other communication protocols, as well as supports blackberry and various Windows mobile devices, XP desktops, notebooks, and tablet PC's. The company was founded in 2003 and is based in Reston, Virginia.

GlycoMimetics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative glycomimetic drugs aimed at addressing significant unmet medical needs associated with diseases influenced by carbohydrate biology. The company’s lead drug candidate, rivipansel, is a pan-selectin antagonist that has completed Phase III clinical trials for treating vaso-occlusive crises in sickle cell disease. Additionally, GlycoMimetics is developing uproleselan, an E-selectin inhibitor that is being tested in combination with chemotherapy for acute myeloid leukemia (AML) and in a Phase III trial for relapsed/refractory AML. The company also offers GMI-1359, which targets E-selectin and a chemokine receptor, having completed Phase I clinical trials, and is involved in developing other candidates, including GMI-1687 and Galectin-3. GlycoMimetics has established research collaborations, including an agreement with the National Cancer Institute and a partnership with Apollomics for the commercialization of uproleselan and GMI-1687. Founded in 2003, the company is headquartered in Rockville, Maryland.

Siperian specializes in master data management (MDM) solutions that help organizations unify critical data about customers, products, and other entities that may be fragmented across various systems. By providing a comprehensive view of essential business information, Siperian enhances operational and analytical processes, allowing companies to make informed decisions and improve customer relationship management. The Siperian MDM Hub™ features a flexible, model-driven platform that adapts to specific business requirements, facilitating faster implementation and delivering a strong return on investment. Its solutions cater to a wide range of industries, including financial services, healthcare, manufacturing, and technology, addressing complex needs such as regulatory compliance and product launches. Siperian collaborates with a network of partners, including major firms like Accenture and IBM, to market and support its offerings. The company has earned the trust of numerous Fortune 500 clients, who rely on Siperian to manage large-scale master data solutions that support both analytical and transactional business needs.

ScoreBoard, Inc. offers innovative software and services designed to assist wireless telecommunications carriers in optimizing their network performance. By collecting and analyzing measured network data, the company enables carriers to explore various scenarios related to network reliability and capacity. This solution addresses the challenges faced by mobile operators, such as resource scarcity and heightened consumer expectations, particularly in a challenging financial environment. Through its offerings, ScoreBoard aims to help carriers better meet their commitments to investors and customers alike.

Highway to Health, (HTH) applies its dynamic Internet expertise to bring innovative online healthcare services and insurance to international travel, study, and commerce. Each year thousands of leisure and business travelers as well as international students and scholars protect themselves, their families, and their travel plans with HTH. Their programs combine comprehensive, competitively priced insurance products with critical travel health information, known as CityHealthProfiles, and online medical assistance services available through HTH TravelersClub. Members enjoy access to their community of pre-selected, contracted physicians in over 100 countries, and their interactive translation guides for brand-name pharmaceuticals and common medical terms and phrases.

ScoreBoard, Inc. offers innovative software and services designed to assist wireless telecommunications carriers in optimizing their network performance. By collecting and analyzing measured network data, the company enables carriers to explore various scenarios related to network reliability and capacity. This solution addresses the challenges faced by mobile operators, such as resource scarcity and heightened consumer expectations, particularly in a challenging financial environment. Through its offerings, ScoreBoard aims to help carriers better meet their commitments to investors and customers alike.

Message Pharmaceuticals is a company that provides Communications systems and more.